Acute Lymphoblastic Leukemia | Topics

Survival Rate Increased Over 2 Decades for Relapsed Ph+ Acute Lymphoblastic Leukemia After Hematopoietic Cell Transplantation
January 15, 2022

Two-year overall survival increased from period between 2000 and 2004 to period between 2015 and 2019 for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic stem cell transplantation.

Adding Eryaspase to Chemotherapy Shows Promise in Patients with ALL at Risk for Hypersensitivity Reactions
December 12, 2021

The infusion of E-Coli- and Erwinia-derived asparaginase therapies combined with chemotherapy appeared to be well tolerated with biological efficacy in patients with acute lymphoblastic leukemia under the age of 55, providing an additional option for patients for whom further asparagine treatment is contraindicated due to toxicity.

Real-World Data of Tisagenlecleucel Comparable With Clinical Trial Findings in Relapsed/Refractory B-Cell ALL
December 12, 2021

A population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia appeared to have comparable real-world benefit from tisagenlecleucel compared with findings from the phase 2 ELIANA trial.

DNA Sequencing of Bone Marrow Is Predictive of ALL Relapse Following Treatment With Tisagenlecleucel
December 02, 2021

DNA sequencing to detect minimal residual disease and eventual relapse was more accurate than flow cytometry for adult and pediatric patients with acute lymphoblastic leukemia who have been treated with tisagenlecleucel.

AUTO1 CAR T Cells Yield Better Safety and Remission Rates in Relapsed/Refractory Adult B-Cell ALL
November 15, 2021

Patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia who were treated with AUTO1 experienced durable responses.

Chinese Researchers Identify Risk Factors for Poor Treatment Response to CAR T Therapy in ALL Patients
October 25, 2021

ASTCT recently published an article in their journal Nucleus detailing CAR T therapy in patients with acute lymphoblastic leukemia.

FDA Approves Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory ALL
October 04, 2021

The FDA has approved the use of CD19-directed CAR T-cell therapy brexucabtagene autoleucel for adult patients with relapsed/refractory precursor acute lymphoblastic leukemia.

Despite Improved Survival Rates in T-ALL, Investigators Seek Further Improvements Through Immunotherapeutics
September 09, 2021

The introduction of targeted therapies and immunotherapeutics may work to improve survival for patients with T-cell acute lymphoblastic leukemia.

Focal 22q11.22 Deletions Associated With Poor Outcomes in Pediatric B-Cell Acute Lymphoblastic Leukemia With IKZF1 Alterations
September 08, 2021

A recent study provides evidence showing that focal 22q11.22 deletions may be correlated with poor outcomes in patients with pediatric B-cell acute lymphoblastic leukemia with alterations in IKZF1.

Vincristine/Dexamethasone Pulse Therapy May be Omitted After 1 Year of Treatment in Pediatric Acute Lymphoblastic Leukemia
September 03, 2021

Pediatric patients with low-risk acute lymphoblastic leukemia may be able to omit treatment with vincristine and dexamethasone pulse therapy after the first year of treatment.